CRISPR Therapeutics (NASDAQ: CRSP)
$39.04
(1.8%)
$0.68
Price as of January 15, 2025, 4:00 p.m. ET
CRISPR Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
CRISPR Therapeutics Company Info
CRISPR Therapeutics is a biotech company using gene therapy to try to correct genetic mutations to treat and cure diseases.
News & Analysis
The Fool has written over 400 articles on CRISPR Therapeutics.
Featured Article
Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts
Cory Renauer | Jan 14, 2025
Featured Article
This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?
Prosper Junior Bakiny | Dec 22, 2024
1 Big New Green Flag for CRISPR Therapeutics' Stock
Alex Carchidi | Dec 20, 2024
2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?
Cory Renauer | Dec 17, 2024
3 Things You Need to Know if You Buy CRISPR Therapeutics Today
Dan Victor | Dec 14, 2024
2 Biotech Stocks to Buy Hand Over Fist in December
Prosper Junior Bakiny | Dec 7, 2024
How to Invest in CRISPR Therapeutics Stock
Lyle Daly | Dec 5, 2024
3 of the Best Growth Stocks You Can Buy for Less than $100
David Jagielski | Dec 5, 2024
Valuation
Podcast Episodes
"The Era of the Gene-Edited Human Is Here"
An investor's look.
Chris Hill | Sep 19, 2022
Breaking Down CRISPR Technology
What investors need to know.
Karl Thiel | Sep 28, 2021
Is Amarin's Fish Oil Pill on Track to Become a Blockbuster?
Plus, how gene-editing company CRISPR Therapeutics just took a big step forward.
Todd Campbell | Nov 22, 2019
Did China’s “Designer Babies” Just Open Pandora’s Box?
What will this mean for healthcare and for the future of society?
Motley Fool Staff | Dec 21, 2018
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.